COMPANION DIAGNOSTICS FOR CANCER AND SCREENING METHODS TO IDENTIFY COMPANION DIAGNOSTICS FOR CANCER BASED ON SPLICING VARIANTS

摘要

A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.

主权项

1. A method of classifying a patient for eligibility for cancer therapy comprising:
a) providing a tissue sample from a patient; b) determining the presence or absence of a PIK3CD transcript without exon 23 in the sample's total mRNA; and c) classifying the patient as eligible to receive a cancer therapy based on the presence or absence of the PIK3CD transcript without exon 23 in the total mRNA of said tissue sample;wherein the absence or low levels of PIK3CD transcript without exon 23 is indicative of said patient's eligibility for cancer therapy.